Drew H. Barzman

Drew H. Barzman

Auto-generated profile, based on publicly available information

Drew H. Barzman

Emergency Medicine, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, United States, 1 513-636-7966

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2013 in Psychiatric Quarterly
Verified
Journal Article
Closed access
PDF file
BPBianca D. Patel
Bianca D. Patel
DBDrew H. Barzman
Drew H. Barzman

1 December 2005 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Closed access
DBDrew H. Barzman
Drew H. Barzman
MDMelissa P. DelBello
Melissa P. DelBello
RKRobert A. Kowatch
Robert A. Kowatch
JWJuliet Warner
Juliet Warner
DRDana Rofey
Dana Rofey
SSStephen M. Strakowski
Stephen M. Strakowski
Objective: The aim of this study was to assess topiramate as adjunctive treatment in children and adolescents hospitalized with bipolar disorders. Methods: Medical records of all children and adolescents with a Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV-TR) (APA, 2000) diagnosis of bipolar disorder, type I, hospitalized for an acute manic, mixed, or depressive episode, were reviewed. The primary outcome measure was the Clinical Global Impression—Severity (CGI-S) score. Results: Twenty-five (25) children and adolescents received topiramate, with a mean final dose of 126 mg/day (range, 25–350 mg). Overall CGI-S scores significantly improved from 5.3 ± 1.0 to 3.5 ± 0.7, and mania CGI-S scores decreased from 5.4 ± 1.0 to 3.3 ± 0.9. Sixteen (16) of 25 (64%) bipolar patients were classified as responders (defined by an endpoint overall CGI-I score of less than or equal to 2). No serious adverse events occurred during treatment. Of 25 patients evaluated, 1 (4%) experienced mild sedation while treated with topiramate. Conclusions: Preliminary results of this retrospective chart review suggest that adjunctive topiramate may be associated with improvements in children and adolescents hospitalized for an acute manic, mixed, or depressive episode. Randomized and controlled trials with adjunctive topiramate in this population are needed to further explore this observation.

1 January 2011
Verified
Journal Article
Closed access
DBDrew H Barzman
Drew H Barzman
LBLauren Brackenbury
Lauren Brackenbury
LSLoretta Sonnier
Loretta Sonnier
BSBeverly Schnell
Beverly Schnell
ACAmy Cassedy
Amy Cassedy
DMDouglas Mossman
Douglas Mossman

1 October 2010 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
DBDrew H Barzman
Drew H Barzman
APAvni Patel
Avni Patel
LSLoretta Sonnier
Loretta Sonnier
JSJeffrey R Strawn
Jeffrey R Strawn
Pediatric aggression is common in human societies, mainly presenting as impulsive aggression or predatory aggression. Numerous psychiatric disorders can contain aggression as a symptom, leading to difficulties in diagnosis and treatment. This review focuses on the biological systems that affect pediatric aggression. We review the hypothalamic–pituitary–adrenal (HPA) axis, the hypothalamic–pituitary–gonadal (HPG) axis, and the mechanisms by which these axes influence the body and mind of aggressive children and adolescents. Although this review focuses on the HPA and HPG axes, it is important to note that other biological systems have relationships with these two axes. Based on the results of the studies reviewed, elevated cortisol concentrations were associated with impulsive aggression, whereas, low levels of cortisol were associated with callous-unemotional traits similar to predatory aggression. Higher levels of dehydroepiandrosterone were correlated with higher levels of aggression as were higher levels of testosterone. However, there have been discrepancies in the results between various studies, indicating the need for more research on hormonal levels and pediatric aggression. In the future, hormonal levels may be useful in determining what treatments will work best for certain pediatric patients.


20 March 2013 in Psychiatric Quarterly
Verified
Journal Article
Closed access
PDF file
DBDrew H. Barzman
Drew H. Barzman
DMDouglas Mossman
Douglas Mossman
KAKacey Appel
Kacey Appel
TBThomas J. Blom
Thomas J. Blom
JSJeffrey Robert Strawn
Jeffrey Robert Strawn
TGThomas D. Geracioti
Thomas D. Geracioti